

Practical Implementation Nursing Science

Effectiveness of Complementary Therapies in the Management of Wounds Among Adult Patients

LITERATURE REVIEW

GLADYS MSISKA (D)
CAROLINE FU (D)
KONDWANI WELLA (D)
ANNIE MSOSA (D)

NOEL MBIRIMTENGERENJI

GIBSON MASACHE

MIRIAM SIMBOTA

MARA CHRIS BANEZ

GENESIS CHORWE-SUNGANI

CAROLYN SUN



*Author affiliations can be found in the back matter of this article

ABSTRACT

Aims: To conduct a systematic review of complementary therapies for wound management.

Methods: An initial search of the literature was conducted using a machine-learning assisted instrument. Based on initial results, literature was hand reviewed by at least two team members for inclusion. Data were extracted and quality was assessed for included articles at the full text level.

Results: 67 articles were included on a variety of complementary therapies for wound management including original research such as randomized controlled trials, non-randomized controlled trials, case reports, and cohort studies that assessed the effectiveness of complementary therapies in the management of wounds among adult patients. Studies assessing the effectiveness of complementary therapies on patients with episiotomies, complementary therapies using body-mind therapies, studies for which the full text was inaccessible, and non-English language studies were excluded. Resulting treatments were honey, maggot debridement, Aloe vera, Calendula officinalis, Hypericum perforatum ointment, dragon's blood, curcumin, banana leaf dressing, potato peels, and tea tree oil.

Conclusion: Honey, maggot debridement, Aloe vera, Calendula officinalis, Hypericum perforatum ointment, dragon's blood, curcumin, banana leaf dressing, and tea tree oil show promise as low cost alternatives for wound management.

CORRESPONDING AUTHOR:

Gladys Msiska

Kamuzu University of Health Sciences, MW

gmsiska@kuhes.ac.mw

KEYWORDS:

Wound management; complementary therapies; complementary alternative medicines; low-resource; low cost alternatives; systematic review

TO CITE THIS ARTICLE:

Msiska, G., Fu, C., Wella, K., Msosa, A., Mbirimtengerenji, N., Masache, G., Simbota, M., Banez, M. C., Chorwe-Sungani, G., & Sun, C. (2023). Effectiveness of Complementary Therapies in the Management of Wounds Among Adult Patients. *Practical Implementation of Nursing Science*, 2(1), pp. 22–53. DOI: https://doi.org/10.29024/pins.31

INTRODUCTION AND BACKGROUND

Acute and chronic wounds remain a problem for both the developing and the developed world (Sibbald et al., 2012; Queen and Harding, 2012; Haagsma et al., 2016). In developed countries, the prevalence of skin breakdown from leg ulcers, pressure ulcers, and diabetic foot ulcers continues to grow as the population ages (Queen & Harding 2012; Posnett & Franks, 2008). In developing countries, injuries due to road traffic accidents and burns are major contributors to the wound care burden, and the unavailability of proper wound care and treatment is a critical challenge (World Health Organization 2009; World Health Organization 2019; World Health Organization 2015). Wound management is costly and therefore largely impractical for developing countries to implement (Benskin, 2013). While effective wound care is available in developing countries, advancements have been associated with escalating healthcare costs (Sen, 2019; Posnett & Franks, 2008). Thus, inexpensive and efficacious wound care strategies for developing countries are needed.

In Malawi, a developing country characterized by low resource clinical settings, the most commonly reported causes of injuries are animal bites (mostly dog bites), road traffic injuries, assaults, burns, and falls (National Statistics Office, 2017; Chokotho et al., 2014). Managing patients with traumatic wound injuries is a challenge in low income countries due to a lack of antiseptics and other materials for wound care. Extensive and infected wounds are common in surgical wards, including wounds that are clean initially and later become infected. Consequently, complementary therapies such as brown sugar, honey, pawpaw, tea, and Aloe vera are used for wound care. These locally available therapies are inexpensive and, if effective, could help mitigate wound care challenges faced by regional health sectors.

However, there is limited rigorous research to guide effective utilization of these complementary therapies (Erwin-Toth 2014). The lack of standardization of naturopathic products interferes with accuracy of dosage and leads to inconsistent delivery of the product, and differences in measured efficacy. These limitations make it difficult to ascertain the effectiveness of complementary therapies. Therefore, the purpose of this review is to evaluate the published evidence on the clinical effectiveness of complementary therapies in wound treatment, particularly for use in resource-poor countries, such as Malawi.

METHODS

This systematic review was guided by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (Moher et al., 2009).

INCLUSION AND EXCLUSION CRITERIA

Articles meeting the following criteria were included 1) randomized controlled trials, non-randomized controlled trials, and observational studies such as case reports and cohort studies which assessed the effectiveness of complementary therapies in the management of wounds among adult patients; 2) studies which assess the effectiveness of complementary therapies in the form of natural products such as honey, Aloe vera, and other similar products; 3) studies assessing the effectiveness of complementary therapies on patients with wound infections, burns, traumatic wounds, diabetic foot ulcers and surgical incisions, pressure sores, trophic ulcers, and venous ulcers; and 4) published from January 1, 2009, through October 31, 2018. The following exclusion criteria were applied: 1) systematic reviews and meta-analyses; 2) studies assessing the effectiveness of complementary therapies on patients with episiotomies; 3) studies assessing the effectiveness of complementary therapies in the form of body-mind therapies, alternative medical systems such as acupuncture, and manipulative and body-based methods such as massage therapy; 4) studies for which the full text was inaccessible; and 5) non-English language studies.

SEARCH STRATEGY

Digitally accessible full-text articles and abstracts were collected and systematized using Ediom's EvidenceEngine, a machine-learning assisted instrument intended to aid health systems in the

clinical value analysis process by providing comprehensive and objective analyses of the latest relevant information (D'Agostino et al., 2018; Rutkowski et al., 2018; Joanna Briggs Institute, 2014). Articles were identified via keyword searches of MedlinePlus, PubMed, Cochrane, Embase, and Google Scholar (Table 1). Hand searches were later conducted from the references lists of any meta-analyses and systematic reviews retrieved.

Msiska et al. Practical Implementation of Nursing Science DOI: 10.29024/pins.31

Table 1 List of Search Terms.

KEYWORD
complementary medicine wound infection
Aloe vera wound infection
"low resource" wound infection
low income intitle:wound
honey wound healing
honey wound infection
curcuma wound infection
curcumin wound healing
Tea tree wound infection
Calendula wound infection
Hypericum perforatum wound infection
potato peel dressing
Banana leaf dressing
Maggot therapy
curcumin healing randomized
curcumin wound randomized
"dragon's blood" + "wound"
Achillea millefolium wound
Salvia miltiorrhiza
Plantago major
Calendula officinalis
Thai Herbal
essential oils (cumin, cinnamon, cardamom and clove)
Lonicera japonica
Centella asiatica
Ixora coccinea
Arnebia euchroma
Embothrium coccineum
Commiphora (balsamowiec)
orange essential oil
Albizzia lebbeck
Justicia secunda
Nigella sativa L. seed oil
Gumbail tree (Cordia africana)
Lantana camara
Terminalia chebula
Pongamia pinnata
Moringa oleifera
Lavandula stoechas L.
Tap/saline water

DATA ANALYSES

Data were abstracted according to year, author, study design, sample size, peer-review status, conflict of interest statement, quality score, intervention, country, outcome measures, study results, strengths, weaknesses, and cost effectiveness. Studies were reviewed for quality at the full text level. This qualitative assessment included establishing the scientific merit of the evidence based on study type, publication date, sample size, peer review status, and conflict of interest. Each study was assessed by two independent reviewers and discrepancies were discussed until resolved.

Msiska et al. Practical Implementation of Nursing Science DOI: 10.29024/pins.31

RESULTS

Figure 1 shows the selection and evaluation process. A total of 67 studies met the inclusion criteria (Figure 1 and Table 2).




Figure 1 Article Selection Flow Diagram.

 Table 2
 Included studies for Each Complementary Therapy.

ALOE VERA							
AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	ATES	
					CONTROL	COMPARISON	TREATMENT
						placebo	Aloe vera cream
Eshghi et al., 2010	RCT	hemorrhoidec-	64	post-operative pain score, immediate		9.24 ± 0.66	9.29 ± 0.81
		tomy		post-operative pain score, 12 hr		8 ± 0.71	5.75 ± 0.9
				post-operative pain score, 24 hrs		6.3 ± 0.70	3.2 ± 0.83
				post-operative pain score, 48 hrs		5.2 ± 0.91	1.8 ± 0.64
				post-operative pain score, two weeks		2.56 ± 0.50	1.16 ± 0.38
				post-operative pain score, four weeks		1.04 ± 0.20	1 ± 0.00
				number completely healed at two weeks		24 per 24	1 per 25
						silver sulfadiazine	Aloe vera cream
Khorasani et al., 2009	RCT	burn	30	mean time to healing (days)		18.73 +/- 2.65	15.9 +/- 2
					control	placebo	Aloe vera cream
Khorasani et al., 2011	RCT	skin graft	45	mean time to epithelization (days)	17 +/- 8.6	9.7 +/- 2.9	8.8 +/- 2.8
						simple dressing	Aloe vera gel
Molazem et al., 2014	RCT	cesarean	06	REEDA score,* 24 hrs		0.60 ± 1.30	0.00 ± 0.00
		section		REEDA score,* eight days		0.11 ± 0.49	0.29 ± 0.99
				percent with 0 REEDA score* (healed), 24 hrs		77.8	100
				percent with 0 REEDA score" (healed), eight days		91.11	93.33
						silver sulfadiazine	Aloe vera + herb cream
Panahi et al., 2012	RCT	burn	111	percent with skin dryness, day 2		27.3	12.5
				percent with skin dryness, day 7		25.5	12.5
				percent with skin dryness, day 14		10.9	7.1
				change in pain severity score, day 2		1.91 ± 2.25	2.61 ± 1.55
				change in pain severity score, day 7		3.78 ± 2.83	5.13 ± 2.82
				change in pain severity score, day 14		4.54 ± 2.83	5.68±3.2

AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES		
					CONTROL CON	COMPARISON	TREATMENT
					star	standard management	Aloe vera added
Schmidt & Greenspoon,	Non-RCT	cesarean	94	mean time to healing (days), vertical incisions	+	47 +/- 18	84 +/- 27
1991		section		mean time to healing (days), transverse incisions	53 +	53 +/- 24	83 +/- 35
				mean time to healing (days), all incisions	53 +	53 +/- 24	83 +/- 28
				number with adverse effects	0		0
					silve	silver sulfadiazine	Aloe vera gel
Shahzad & Ahmed,	RCT	burn	50	mean time to healing (days)	24.2	24.24 +/- 11.16	11 +/- 4.18
2013				mean time to total pain relief (days)	26		21
				number who developed wound colonization	22		16
					silve	silver sulfadiazine	Aloe vera mucillage
Thamlikitkul et al., 1991	RCT	burn	38	percent with complete healing/epithelization	39		55
				percent with partial healing/epithelization	7 7		40
				percent with no healing/epithelization	17		5
				percent with side effects	7 77		70
				percent with no side effects	39		35
				percent with satisfactory patient rating	28		07
				percent with unsatisfactory patient rating	17		5
					iom	moist saline gauze	Acemannan hydrogel (Aloe vera)
Thomas et al., 1998	RCT	pressure ulcer	30	percent completely healed	99		63
* Higher REEDA score indicates less healing	ates less healing.						
BANANA LEAVES							
AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES		
					CONTROL CON	COMPARISON	TREATMENT
							banana leaves
Guenova et al., 2013	Prospective	post-surgical	43	number with pain score one			6 per 43
	case series			number with infection, one week			0
				number with infection, two weeks			0

FIRST ALTHONO, YEAR STUDY DESIGN WOUND TYPE N OUTCOME MEASURE (UNITS) CONTROL CONDARISON TREATMENT								
mean healing time (weeks) percent colonized, baseline percent infected, baseline percent infected, 30 weeks percent with no infection, day 3 percent with no infection, day 11 percent with no infection, day 11 percent with poor epithelialization, day 1 percent with poor epithelialization, day 11 percent with foir epithelialization, day 11 percent with poor epithelialization, day 11 percent with poor epithelialization, day 11 percent with poor epithelialization at day 5 mean percentage of wound healing at day 5 mean percentage of wound healing at day 10 mean percentage of wound healing at day 14 mean percentage of wound healing at day 14 munber of wound infections per starting sample 1 percent with number of wound infections per starting sample 1 percent with poor epithelialization at day 14 1 percent with percentage of wound healing at day 14 1 percent with percentage of wound healing at day 14 1 percent with percentage of wound healing at day 14 1 percent with percentage of wound healing at day 14	FIRST AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	S	
mean healing time (weeks) percent colonized, baseline percent infected, baseline percent infected, a0 weeks percent infected, 30 weeks percent with no infection, day 3 percent with no infection, day 11 percent with fair epithelialization, day 7 percent with fair epithelialization, day 11 percent with fair epithelialization, d							COMPARISON	TREATMENT
percent colonized, baseline percent colonized, baseline percent colonized, baseline percent infected, 30 weeks percent infected, 30 weeks percent infected, 30 weeks percent with no infection, day 7 percent with no infection, day 11 percent with foir epithelialization, day 7 percent with foir epithelialization, day 11 percent with foir epithelialization, day 11 percent with foor epithelialization, day 11 percent with foor epithelialization, day 11 percent with foor epithelialization, day 11 percent with poor epithelialization, day 11 percent with foor epithelialization, day 11 percent with foor epithelialization, day 11 percent with boor epithelialization, day 11 percent with foor epithelialization and 14 percent control infections per starting sample percent colonized infercions per starting sample								Calendula oil
percent colonized, baseline percent colonized, 30 weeks percent infected, 30 weeks percent infected, 30 weeks control doy 1 percent with no infection, day 7 percent with foir epithelialization, day 11 percent with foor epithelialization, day 11 percent with poor epithelialization, day 11 percent with poor epithelialization, day 11 percent with poor epithelialization, day 11 control control control control control control control doy 2 doy 3 doy 4,24 mean percentage of wound healing at day 5 mean percentage of wound healing at day 5 mean percentage of wound healing at day 7 mean percentage of wound healing at day 1 mean percentage 1 mean percentage 5 mean 1 mean	Buzzi et al., 2016	Prospective	pressure ulcer	41	mean healing time (weeks)			15.5 ± 6.7
percent colonized, 30 weeks percent infected, 30 weeks percent infected, 30 weeks OUTCOME MEASURE (UNITS) percent with no infection, day 7 percent with no infection, day 7 percent with poor epithelialization, day 7 percent with foor epithelialization, day 11 percent with poor epithelialization, day 11 percent with foor epithelialization and y 11 percent with y 11 percent with y 11 pe		Case Series			percent colonized, baseline			26.8
percent infected, 30 weeks CONTROL COMPARISON CONTROL COMPARISON CONTROL COMPARISON CONTROL COMPARISON Dercent with no infection, day 7 17.5 Dercent with fair epithelialization, day 7 34.2 Dercent with foor epithelialization, day 11 33.7 Dercent with fo					percent colonized, 30 weeks			14.6
percent infected, 30 weeks OUTCOME MEASURE (UNITS) Percent with no infection, day 3 percent with no infection, day 7 percent with no infection, day 7 percent with poor epithelialization, day 7 percent with fair epithelialization, day 11 percent with poor epithelialization at day 13 mean percentage of wound healing at day 3 mean percentage of wound healing at day 10 mean percentage of wound healing at day 10 mean percentage of wound healing at day 10 mean percentage of wound healing at day 14 number of wound infections per starting sample 1 per 55					percent infected, baseline			48.8
percent with no infection, day 3 percent with no infection, day 3 percent with no infection, day 7 percent with no infection, day 1 percent with poor epithelialization, day 7 percent with poor epithelialization, day 11 percent with poor epithelialization at day 11 percent with poor epithelialization at day 3 mean percentage of wound healing at day 5 mean percentage of wound healing at day 10 mean percentage of wound healing at day 14 number of wound infections per storting sample 1 per 55					percent infected, 30 weeks			2.4
percent with no infection, day 7 percent with no infection, day 7 percent with no infection, day 7 percent with good epithelialization, day 7 percent with fair epithelialization, day 11 percent with boor epithelialization, day 11 percent with boor epithelialization, day 11 percent with hoor epithelialization, day 11 percent with fair epithelialization, day 11 percent fair epithelialization, day 11 percent fair epithelialization, day 11 percent fair fair fair fair fair fair fair fair	CURCUMIN							
control COMPARISON 28 percent with no infection, day 3 16.7 2 percent with no infection, day 7 17.5 2 percent with no infection, day 11 17.5 3 percent with good epithelialization, day 7 34.2 3 percent with poor epithelialization, day 7 48.2 4 8.2 5 percent with good epithelialization, day 11 33.7 5 percent with fair epithelialization, day 11 38.6 6 percent with poor epithelialization, day 11 38.6 7 percent with fair epithelialization, day 11 38.6 8 control 27.6 9 mean percentage of wound healing at day 3 4.74 9 mean percentage of wound healing at day 5 43.9 9 mean percentage of wound healing at day 10 61.95 9 mean percentage of wound healing at day 10 61.95 9 mean percentage of wound healing at day 10 61.95 1 1 per 55	AUTHOR, YEAR	STUDYDESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	S	
28 percent with no infection, doy 3 16.7 percent with no infection, doy 7 17.5 percent with no infection, doy 11 17.9 percent with good epithelialization, day 7 17.5 percent with boor epithelialization, day 71 48.2 percent with poor epithelialization, day 11 33.7 percent with poor epithelialization, day 11 27.6 percent with poor epithelialization, day 11 38.6 percent with poor epithelialization, day 11 38.6 percent with poor epithelialization, day 11 27.6 percent with boor epithelialization, day 11 38.6 percent with boor epithelialization, day 11 38.6 percent with boor epithelialization, day 11 38.6 a mean percentage of wound healing at day 3 4.74 mean percentage of wound healing at day 5 43.9 mean percentage of wound healing at day 10 61.95 mean percentage of wound healing at day 10 61.95 mean percentage of wound healing at day 14 78.1 number of wound infections per starting sample 1 per 55							COMPARISON	TREATMENT
percent with no infection, day 7 percent with no infection, day 11 percent with no infection, day 11 percent with fair epithelialization, day 7 percent with foir epithelialization, day 7 percent with good epithelialization, day 11 percent with good epithelialization, day 11 percent with good epithelialization, day 11 percent with foir epithelialization, day 11 percent with poor epithelialization, day 11 percent with foir epithelialization, day 11 percent with foor epithelialization, day 11 percent with foir epithelialization, day 1 percent with foir epithelializ	Choudhary et al., 2012	Self-controlled	burn	228	percent with no infection, day 3		16.7	52.2
percent with no infection, day 11 percent with good epithelialization, day 7 percent with fair epithelialization, day 7 percent with boor epithelialization, day 11 percent with boor epithelialization, day 11 percent with fair epithelialization, day 11 percent with boor epithelialization, day 11 percent with fair epithelializati		Case-control*			percent with no infection, day 7		17.5	61.4
percent with good epithelialization, day 7 percent with fair epithelialization, day 7 percent with poor epithelialization, day 11 percent with good epithelialization, day 11 percent with good epithelialization, day 11 percent with fair epithelialization, day 11 percent with poor epithelialization, day 11 percent with fair epithelialization, day 14 percent with fair epithelialization, day 17 percent with fair epithelialization, day 14 percent with fair epithelialization, day 17 percent with fair epith					percent with no infection, day 11		17.9	84.2
percent with fair epithelialization, day 7 percent with poor epithelialization, day 11 percent with good epithelialization, day 11 percent with good epithelialization, day 11 percent with poor epithelialization, day 12 percent with poor epithelialization, day 11 percent with poor epith					percent with good epithelialization, day 7		17.5	61.4
percent with poor epithelialization, day 7 percent with good epithelialization, day 11 percent with fair epithelialization, day 11 percent with poor epithelialization, day 11 percent with poor epithelialization, day 11 OUTCOME MEASURE (UNITS) Mean percentage of wound healing at day 5 mean percentage of wound healing at day 7 mean percentage of wound healing at day 10 mean percentage of wound healing at day 10 mean percentage of wound healing at day 14 mean percentage of wound healing at day 15 mean percentage 15 mean pe					percent with fair epithelialization, day 7		34.2	29.8
percent with good epithelialization, day 11 percent with fair epithelialization, day 11 percent with poor epithelialization, day 11 percent with poor epithelialization, day 11 OUTCOME MEASURE (UNITS) mean percentage of wound healing at day 3 mean percentage of wound healing at day 7 mean percentage of wound healing at day 7 mean percentage of wound healing at day 10 mean percentage of wound healing at day 16 mean percentage 10 mean percent					percent with poor epithelialization, day 7		48.2	8.7
percent with fair epithelialization, day 11 percent with poor epithelialization, day 11 OUTCOME MEASURE (UNITS) mean percentage of wound healing at day 5 mean percentage of wound healing at day 7 mean percentage of wound healing at day 10 mean percentage of wound healing at day 14 mean percentage of wound healing at day 15 mean percentage of wound healing at day 16					percent with good epithelialization, day 11		33.7	85.1
percent with poor epithelialization, day 11 OUTCOME MEASURE (UNITS) CONTROL COMPARISON mean percentage of wound healing at day 5 mean percentage of wound healing at day 7 mean percentage of wound healing at day 10 mean percentage of wound healing at day 10 mean percentage of wound healing at day 14 TB-155					percent with fair epithelialization, day 11		27.6	10.1
OUTCOME MEASURE (UNITS) CONTROL COMPARISON mean percentage of wound healing at day 5 mean percentage of wound healing at day 7 mean percentage of wound healing at day 10 mean percentage of wound healing at day 10 mean percentage of wound healing at day 14 TR.1 purple 55					percent with poor epithelialization, day 11		38.6	4.8
STUDY DESIGN WOUND TYPE N OUTCOME MEASURE (UNITS) EFFECT ESTIMATES RCT skin tag 60 mean percentage of wound healing at day 5 4.74 mean percentage of wound healing at day 1 23.5 mean percentage of wound healing at day 10 61.95 mean percentage of wound healing at day 10 61.95 mean percentage of wound healing at day 14 78.1 number of wound infections per starting sample 1 per 55	* Patients given both con	itrol and treatment (2 wounds per patie	ent).				
STUDY DESIGN WOUND TYPE N OUTCOME MEASURE (UNITS) EFFECT ESTIMATES RCT skin tag 60 mean percentage of wound healing at day 3 4.74 RCT mean percentage of wound healing at day 7 23.5 mean percentage of wound healing at day 7 43.9 mean percentage of wound healing at day 10 61.95 mean percentage of wound healing at day 14 78.1 number of wound infections per starting sample 1 per 55	DRAGON'S BLOOD							
RCT skin tag 60 mean percentage of wound healing at day 3 4.74 mean percentage of wound healing at day 5 23.5 mean percentage of wound healing at day 7 43.9 mean percentage of wound healing at day 10 61.95 mean percentage of wound healing at day 10 61.95 mean percentage of wound healing at day 14 78.1 number of wound infections per starting sample 1 per 55	AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	S	
RCT skin tag 60 mean percentage of wound healing at day 3 4.74 mean percentage of wound healing at day 7 23.5 mean percentage of wound healing at day 10 43.9 mean percentage of wound healing at day 10 61.95 mean percentage of wound healing at day 14 78.1 number of wound infections per starting sample 1 per 55							COMPARISON	TREATMENT
mean percentage of wound healing at day 523.5mean percentage of wound healing at day 1043.9mean percentage of wound healing at day 1061.95mean percentage of wound healing at day 1478.1number of wound infections per starting sample1 per 55	Namjoyan et al., 2016	RCT	skin tag	09	mean percentage of wound healing at day 3		4.74	31.06
percentage of wound healing at day 7 percentage of wound healing at day 10 percentage of wound healing at day 14 er of wound infections per starting sample 1 per 55			removal		mean percentage of wound healing at day 5		23.5	63.77
percentage of wound healing at day 10 61.95 percentage of wound healing at day 14 78.1 er of wound infections per starting sample 1 per 55					mean percentage of wound healing at day 7		43.9	77.8
percentage of wound healing at day 14 78.1 er of wound infections per starting sample 1 per 55					mean percentage of wound healing at day 10		61.95	89.14
1 per 55					mean percentage of wound healing at day 14		78.1	95.73
					number of wound infections per starting sample		1 per 55	0 per 45

HONEY							
AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	ATES	
					CONTROL	COMPARISON	TREATMENT
Baghel et al., 2009	RCT	burn	78	mean time to healing (days)		32.68	18.16
				percent with complete healing, two months		37	81
				percent with wound sterilization, 21 days		36.5	100
						silver sulfladiazene	honey
Bangroo et al., 2005	RCT	burn	99	mean time to appearance of healthy granulation (days)		12.8	6.7
				number with infection, baseline		24 per 32	25 per 32
				number with infection, seven days		21 per 32	2 per 32
				number with contractures		5 per 32	2 per 32
						Σ	Medihoney
Biglari et al., 2012°	Prospective	pressure ulcer	20	percent with complete healing, four weeks			06
	Case Series			percent with sterilization, one week			100
				number of negative effects			0
						none	Surgihoney
Dryden et al., 2014	non-RCT	oncology	09	number with line colonization, baseline		4 per 30	2 per 30
		vascular lines		number with line colonization, during evaluation		6 per 30	0 per 30
				number with line colonization, end of evaluation		6 per 30	0 per 30
				number of pain events		2 per 30	2 per 30
				number of itching/irritation events		1 per 30	4 per 30
				number of rashes		1 per 30	3 per 30
				discharge at exit site		0 per 30	1 per 30
					saline	phenytoin	sterilized honey
Dubhashi & Sindwani,	non-RCT	infections,	150	percent of wound reduction, three weeks	8.07	15.8	20.66
2015		ulcers		mean time to wound sterilization (days)	14.94 ± 2.56	9.28 ± 2.03	8.4 ± 1.71
				mean pain score, day 5	6.72 ± 0.64	5.54 ± 0.68	5.10 ± 0.79
				mean pain score, day 10	5.02 ± 0.77	3.76 ± 0.77	3.06 ± 0.91
				mean pain score, day 15	4.32 ± 0.79	2.68 ± 0.65	2.06 ± 0.65

HONEY							
AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	\TES	
					CONTROL	COMPARISON	TREATMENT
				mean pain score, day 20	3.14 ± 0.76	1.20 ± 0.45	1.20 ± 0.45
				mean length of hospital stay (days)	4758 ± 10.19	29.6 ± 5.64	24.63 ± 5.20
						povidone iodine	honey
Gulati et al., 2014	RCT	chronic	42	percent with complete healing, six weeks		0	31.82
				median reduction wound surface area (cm²), six weeks		2.3	3.8
				median reduction in pain score, baseline to six weeks		2	9
				median change in VAS' and comfort score (positive)		2	5
						silver sulfadiazine	honey
Gupta et al., 2011	Retrospective	burn	108	mean time to healing (days)		32.68	18.16
	Cohort			percent with wound sterilization, 21 days		36.5	100
				percent with complete healing		37	81
						IntraSite Gel	monofloral aloe honey
Ingle et al., 2006♭	RCT	shallow	82	mean healing time (days), shallow wounds		17.12 (11.7 – 22.5)	16.08 (12.3 – 19.9)
		wounds, abrasions		mean healing time (days), abrasions		16.53 (12.3 – 20.8)	17.13 (13.1 – 21.1)
				percent of patients reporting itching		31	27
				cost per gram (Rand)		0.433	0.014
				cost per patient (Rand)		12.06	0.49
						usual care	Manuka honey dressing
Jull et al., 2008°	RCT	venous ulcer	368	percent with complete healing, 12 weeks		49.7	55.6
				mean time to healing (days)		65.3	63.5
				mean reduction from baseline ulcer area (%)		65.5	74.1
				percent patients with infection episodes		22.1	17.1
				number of patients reporting adverse events		84 per 181	111 per 187
				number of patients reporting pain		18 per 181	47 per 187
				mean total cost per patient (NZD)		972.68	917

ALIAC:							
HONEY							
AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	ТЕS	
					CONTROL	COMPARISON	TREATMENT
						conventional dressing (saline)	Medihoney tulle
Kamaratos et al., 2012	RCT	diabetic ulcer	63	percent healed during follow-up period		06	76
				mean time to healing (days)		43 ± 3	31 ± 4
				number with infection, baseline		31 per 31	32 per 32
				number with infection, one week		20 per 31	7 per 32
				number with infection, two weeks		8 per 31	2 per 32
				number with infection, four weeks		4 per 31	0 per 32
				percent needing antibiotics		29	0
						silver-coated bandage	honey-coated bandage
Lund-Nielsen et al.,	RCT	malignant	69	median decrease in wound size (cm2)		8	15
2011ª		(cancer)		number with improved wound cleanliness		17 per 35	23 per 34
						mafenide acetate	honey dressing
Maghsoudi et al.,	RCT	burn	100	percent completely healed, day 7		72	84
2011 ^e				percent completely healed, day 21		48	100
				number with infection (out of 50), baseline		† †	94
				number with infection (out of 50), day 7		12	16
				number with infection (out of 50), day 21		9	1
						silver sulfadiazine	honey
Malik et al., 2010	RCT	burn	150	mean time to healing (days)		15.62 ± 4.40	13.47 ± 4.06
				number with infection		29 per 150	6 per 150
				number who "failed to heal"		29 per 150	8 per 150
				number needing skin graft, two weeks		29 per 150	8 per 150
						povidone iodine	honey
Marshall et al., 2005	RCT	toenail surgery	51	mean time to healing (days), all		25 ± 8.70	33 ± 15.71
				mean time to healing (days), total avulsion		30 ± 10.62	44 ± 7.88
				mean time to healing (days), partial avulsion		24 ± 7.23	18 ± 8.45
				number of patients who developed infection		0 per 24	1 per 27
				mean VAS' value for pain (cm)		1.99 ± 1.41	1.86 ± 1.67

AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	ATES	
					CONTROL	COMPARISON	TREATMENT
						silver sulfadiazine	pure honey
Mashhood et al., 2006	RCT	burn	20	percent healed, two weeks		20	52
				percent healed, four weeks		09	100
				time to all patient wounds healed (weeks)		9	4
				time to all patients relieved of pain (weeks)		4	3
				percent with bacterial growth, baseline		76	80
				time to all patient wounds sterilized (weeks)		5	3
						paraffin tulle gras	active Manuka honey
McIntosh & Thomson,	RCT	toenail surgery	100	mean time to healing (days), all		39.98 ± 25.42	40.30 ± 18.21
2006				mean time to healing (days), total avulsion		52.03 ± 21.3	45.28 ± 18.03
				mean time to healing (days), partial avulsion		19.62 ± 9.31	31.76 ± 18.8
				mean VAS' value for pain (cm)		1.57 ± 1.3	1.60 ± 1.22
				mean pain score during dressing change		1.23 ± 0.84	1.26 ± 1.09
						silver sulfadiazine	pure undiluted honey
Memon et al., 20059	RCT	burn	80	time to all patients healed (days)		97	30
				mean time to healing (days)		20	15.3
				percent with infection (bacteria colonization)		80	0
				number with minor complications after healing		30 per 40	9 per 40
						intralesionalglucantime	topical honey added
Nilforoushzadeh et al.,	RCT	Leishmaniasis	06	percent with complete healing		71.1	51.1
2007		ulcer		mean time to healing (weeks)		6.3 ± 2.29	7.04 ± 3.09
				attrition rate		10 per 45	13 per 45
						conventional treatment	Medihoney™ antibacterial honey
Robson et al., 2009	RCT	secondary	105	median time to healing (days)		140	100
		Intention		healing rate, 12 weeks (%)		34.0 (22.3, 49.5)	46.2 (32.9, 61.7)
				healing rate, 24 weeks (%)		63.3 (48.6, 77.9)	72.7 (57.3, 86.1)
				median time to 50% reduction in wound area (days)		95	32

ACTION, IEAN	STODY DESIGN	WOUND I THE	Z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	IATES	
					CONTROL	COMPARISON	TREATMENT
				percent with 50% reduction in wound area, 12 weeks		70.5 (57.1, 82.8)	68.2 (54.4, 81.2)
				percent with 50% reduction in wound area, 24 weeks		80.1 (66.4, 90.9)	94.0 (79.1, 99.4)
				attrition rate		3 per 53	4 per 52
				number with adverse events		5 per 53	7 per 52
						povidone iodine	pure honey
Shukrimi et al., 2008	RCT	diabetic ulcer	30	mean time to healing (days)		15.4	14.4
						Eusol dressing	honey
Subrahmanyam &	RCT	gangrene	30	mortality rate		2 per 16	1 per 14
Ugane, 2004				number with clearance of slough, day 7		8 per 16	8 per 14
				number with clearance of slough, day 10		2 per 16	1 per 14
				number with clearance of slough, day 14		3 per 16	5 per 14
				percent with healthy granulation, one week		18.7	28.5
				number requiring secondary suturing		9 per 16	9 per 14
				mean length of hospital stay (days)		32	28
						silver sulfadiazine	pure undiluted honey
Subrahmanyam, 1991	RCT	burn	104	mean time to healing (days)		13.4	7.4
				number with infection, baseline		41 per 52	43 per 52
				number with infection, seven days		38 per 52	4 per 52
				number of complications		16 per 32	2 per 52
						OpSite®	honey gauze
Subrahmanyam,	RCT	burn	95	mean time to healing (days)		15.3	10.8
Iggsan				number with infection, baseline (day 1)		9 per 46	10 per 46
				number with infection, after seven days (day eight)		17 per 46	8 per 46

HONEY							
AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	TES	
					CONTROL	COMPARISON	TREATMENT
				number with infection, seven days		6 per 25	8 per 25
				number with infection, 21 days		3 per 25	1 per 25
						honey dressing	tangential excision and graft
Subrahmanyam, 1999"	RCT	burn, skin graft		mean blood replaced units (% blood volume)		21±15	35±12
				mortality rate		3 per 25	1 per 25
				number with 100% graft take (of those who received grafts)		2 per 11	19 per 24
				rate of infection per swab cultures taken		42 per 123	7 per 71
				mean length of antibiotic treatment (days)		32±18	16±3
				mean length of hospital stay		46±19	21 ± 4
				number with excellent or good wound appearance, three months		12 per 22	22 per 24
						Vaseline gauze	raw honey (Jambhul)
Subrahmanyam, 2015	RCT	skin graft	100	percent with pain assessment none or mild		88	06
				percent with excellent wound appearance patient rating		68.1	69.5
				number with epithelization/healing, day 7		39 per 50	48 per 50
				number with epithelization/healing, day 10		38 per 50'	50 per 50
						Manuka honey	honey
Thomas et al., 2011	Retrospective	post-surgical	17	number with complete healing			15 per 17
	Conort			mean time to healing (days)			65
				median time to healing (days)			64
				number of adverse events			3 per 17
					paraffin tulle (standard)	Manuka honey	nanocrystalline silver
Tsang et al., 2017°	RCT	diabetic ulcer	31	wound size reduction rate (%/week)	76.91	86.24	97.45
				slope of wound reduction over time	2.883	9.337	20.573
				number of microorganism species, baseline	2.00 ± 1.25	1.56 ± 1.59	1.00 ± 1.00

-	_
	٠
₹	コ
4	_
ç	=
(2
Ċ	7

HONEY						
AUTHOR, YEAR	STUDY DESIGN	STUDY DESIGN WOUND TYPE N	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	IATES	
				CONTROL	COMPARISON	TREATMENT
			estimated marginal mean number of microorganisms	1.36	1.17	0.86
			number of adverse events	4 per 10	1 per 10	1 per 11

^{*} VAS = Visual analogue scales.

HYPERICUM PERFORATUM

AUTHOR, YEAR	STUDY DESIGN	STUDY DESIGN WOUND TYPE N	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	TES	
					CONTROL	COMPARISON	TREATMENT
					NO TREATMENT	PLACEBO OINTMENT	H. PERFORATUM OINTMENT
Samadi et al., 2010	RCT	Cesarean	125,	REEDA score,° day 10 postpartum	0.79 ± 1.17	0.75 ± 1.08	0.19 ± 0.50
		section	114	hypertrophic scar VSS score ^b , day 40 postpartum	5.50 ± 0.92	5.03 ± 1.29	3.32 ± 1.54
				patient satisfaction with scarring rate (%)	89	76	06
				attrition rate due to treatment"	0 per 32	0 per 40	1 per 44

 $^{^*19}$ lost to follow up on day 10 (n = 125); nine more lost to follow up on day 40 (n = 114).

a. Negative effects included blood sugar derailment in diabetic patients, allergies.

b. Only compared non-infected wounds, outcome differences not significant between treatment.

c. All patients received compression bandaging, for usual care, RNs determined appropriate dressing (alginate, hydrofibre, hydrocolloid, foam, hydrogel, non-adherent, iodine or silver dressings), quality of life scores (4 scales) at 12 weeks not significantly different between groups.

d. Patients with reduced wound size had longer median survival, 387 days vs 134.

e. 50 patients per treatment arm.

f. Healing = complete re-epithelialization, VAS = Visual analogue scales, 100mm.

g. Unprocessed (raw) honey; reported different time points for healing response for different arms.

h. Reason given for attrition was "progression of their lesions."

i. Analyzed data from patients up to point of leaving study, adverse events included death, pain, wound deterioration.

[.] Found similar outcomes for both groups, described adverse events (infections, pain, discharge) and cost did not provide all numbers for comparison.

k. OpSite® is a bio-occlusive, moisture-permeable polyurethane dressing.

I. Forty patients treated with honey gauze, 24 treated with amniotic membrane, inconsistency in results reported in text versus table.

m. No allergies or other side effects observed; similar pain relief observed.

n. Language unclear regarding mortality.

o. The percentage of area reduction in "week y" was (ulcer area of week 0 - ulcer area of week y//ulcer area of week 0 imes 100%

^{**}Mentions one patient withdrawal due to H. perforatum ointment but not at what stage of the study.

a.REEDA score includes redness, edema, ecchymosis, discharge, and approximation.

b.VSS, Vancouver scar scale.

Author, Yeak STUDY DESIGN WOUND TYPE N OUTCOME MEASURE (UNITS) CONTROL COMPASSON TREATMENT	MAGGOT WOUND THERAPY	HERAPY						
CONTROL COMPARISON	AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMA	TES	
Cose Series diobetic ulcor 11 mean duration of trachment (days) hydroget bragged timose attition rate (unrelated complications) hydroget bragged timose timose (unrelated complications) hydroget bragged timose ti						CONTROL	COMPARISON	TREATMENT
Crose Series diabetic ulcer 11 mean duration of treatment Implications Injury Residue Injury R								larvae
Processor	Azad, 2016	Case Series	diabetic ulcer	11	mean duration of treatment (days)			30.27
RCT culcer 267 coverage estimated cost per application (£) 1.50 ± 0 111.90 ± 33.6 mean number of applications per patient 9.2 ± 27.78 1.44 ± 1.06 mean number of applications per patient 9.2 ± 27.78 1.44 ± 1.06 mean duration of treatment (days) 4.3.7 ± 51.76 12.84 ± 11.47 mean annual cost (£)* 12.60 ± 0.27 12.64 ± 11.47 mean annual cost (£)* 12.60 ± 0.27 12.64 ± 11.47 mean inne to healing (days)* 26.02 ± 20.27 2					number healed after treatment			10 per 11
RCT u/cer 267 overage estimated cost per application (E) 150 ± 0 11130 ± 33.6 Common cost (E) 11130 ± 33.6 11130 ± 33					attrition rate (unrelated complications)			1 per 11
RCT utcer 267 overage estimated cost per application (E) 1.50 ± 0 11190 ± 33.6 mean number of applications per patient 9.2 ± 27.78 1.46 ± 1.06 mean number of applications per patient 4.317 ± 51.76 1.28 ± ± 11.47 mean unaction of treatment (days) 1.976.4 (1521.4 1.28 ± ± 11.47 mean unaction of treatment (days) 2.06.5 (202.7 to 200.2) 2.00.2) AALYS* OALYS* 0.540 (0.489 to 200.2) mean unactionsted utility weights, baseline (value, %) 0.539, 0.317 0.562, 0.33 value, %) mean unactiusted utility weights, six months 0.556, 0.317 0.562, 0.33 value, %) woulde, %) 0.556, 0.317 0.562, 0.33 value, %) mean unactiusted utility weights, six months 0.556, 0.317 0.561, 0.381 value, %) mean unactiusted utility weights, in memonths 0.556, 0.317 0.561, 0.381 value, %) mean unactiusted utility weights, in months 0.556, 0.315 0.561, 0.381 value, %) mean unactiusted utility weights, in months 0.556, 0.317 0.565, 0.332 value, %) mean unactius of treatme						hydrogel	bagged larvae	loose larvae
Mean number of applications per patient 9.2 ± 27.78 1.46 ± 1.06	Dumville, 2009c	RCT	ulcer	267	average estimated cost per application (£)	1.50 ± 0	111.90 ± 33.6	71.79 ± 13.40
Prospective					mean number of applications per patient	9.2 ± 27.78	1.46 ± 1.06	1.44 ± 1.22
Prospective 1976.4 (15214 1976.4 (15214 1976.4 (15214 1976.4 (15214 1976.4 (15214 1976.4 (15212) Prospective 435° 260.20.27 to 260.2					mean duration of treatment (days)	43.17 ± 51.76	12.84 ± 11.47	11.95 ± 9.11
Accordance Proceeding (days)* 206.5 (202.7 to 20.5 mean time to healing (days)* 206.5 (202.7 to 20.5 mean unadjusted utility weights, baseline (value, %) 0.559, 0.317 0.560, 0.33 0.434, 0.342					mean annual cost $(\pounds)^d$	1976.4 (1521.4 to 2500.2)		2073.1 (1724.4 to 2433.4)
Mean unadjusted utility weights, baseline (value, %) 0.539, 0.317 0.562, 0.33					mean time to healing (days)⁴	206.5 (202.7 to 260.2)		204.1 (207.9 to 248.3)
Prospective ulcer 435° D.559, 0.313 0.434, 0.342 mean unadjusted utility weights, three months (value, %) 0.559, 0.317 0.562, 0.33 0.562, 0.33 mean unadjusted utility weights, six months (value, %) mean unadjusted utility weights, nine months (value, %) 0.566, 0.301 0.588, 0.339 mean unadjusted utility weights, nine months (value, %) mean unadjusted utility weights, 12 months (0.615, 0.322 0.561, 0.381 Prospective (value, %) mean unadjusted utility weights, 12 months (0.615, 0.322 0.565, 0.382 mean number of treatments 9.4 mean number of treatments 9.4 mean duration of treatment (days) 9.4 mean duration of treatment (days) 9.4					QALYs⁴	0.540 (0.489 to 0.589)		0.551 (0.505 to 0.591)
Mean unadjusted utility weights, three months (value, %) 0.556, 0.317 0.562, 0.33 Mean unadjusted utility weights, six months (value, %) 0.566, 0.301 0.588, 0.339 Mean unadjusted utility weights, nine months (value, %) 0.628, 0.315 0.561, 0.381 Mean unadjusted utility weights, nine months (value, %) 0.615, 0.322 0.565, 0.382 Mean unadjusted utility weights, 12 months (value, %) 1arvae, caged application Prospective (value, %) Mean number of treatments 9.4 Mean number of treatments 9.4 Mean number of treatments 9.4 Mean duration of treatment (days) mean duration of treatment (days)					mean unadjusted utility weights, baseline (value, %)	0.539, 0.313	0.434, 0.342	0.534, 0.301
Prospective Case Series ulcer 4.35* percent of cases percent of cases percent of treatments 0.566, 0.301 0.588, 0.339 Prospective Case Series ulcer 4.35* percent of cases 9.4 Prospective Case Series mean number of treatments 9.4 Prospective Case Series median number of treatment (days) 9.4					mean unadjusted utility weights, three months (value, %)	0.559, 0.317	0.562, 0.33	0.551, 0.343
mean unadjusted utility weights, nine months (0.628, 0.315) (0.561, 0.381) mean unadjusted utility weights, 12 months (0.615, 0.322) (0.565, 0.382) (value, %) (value, %) (value, %) Prospective ulcer 4.35 percent of cases (Case Series mean number of treatments (mean number of treatments (mean duration of treatment (days)) median duration of treatment (days) (0.615, 0.322) (0.565, 0.382) median duration of treatment (days) (0.615, 0.322) (0.565, 0.382) median duration of treatment (days) (0.615, 0.322) (0.565, 0.382) median duration of treatment (days) (0.615, 0.322) (0.565, 0.382)					mean unadjusted utility weights, six months (value, %)	0.566, 0.301	0.588, 0.339	0.596, 0.334
Prospective Case Series ulcer 435 mean number of treatments porcent (days) porcent (days) median number of treatment (days) median duration of treatment (days) p.4					mean unadjusted utility weights, nine months (value, %)	0.628, 0.315	0.561, 0.381	0.608, 0.345
Prospective ulcer 435 percent of cases Case Series median number of treatments median number of treatment (days) median duration of treatment (days) median duration of treatment (days) median duration of treatment (days)					mean unadjusted utility weights, 12 months (value, %)	0.615, 0.322	0.565, 0.382	0.630, 0.329
Prospective oldcer 435 percent of cases Case Series							larvae, caged application	larvae, direct application"
median number of treatments median duration of treatment (days) median duration of treatment (days)	Gilead, 2012	Prospective	ulcer	435	percent of cases		9.6	90.6
(S		Case series			mean number of treatments			2.9
(S					median number of treatments			2
					mean duration of treatment (days)			4.6
					median duration of treatment (days)			3

MAGGOT WOUND THERAPY	RAPY						
AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	ATES	
					CONTROL	COMPARISON	TREATMENT
				percent with complete debridement			82.1
				percent with partial debridement			16.8
				percent reporting increase pain			38
				attrition rate (due to pain)			5 per 435
							bagged larvae
Hwang, 2011	Case Series	post-surgical	2	mean duration of treatment (weeks)			5.2
		and infected*		mean number of treatment cycles			8.8
				mean wound size before treatment (cm)			24.2 ± 3.3
				mean wound size after treatment (cm)			11.8 ± 4.5
				mean difference in wound size, before-after (cm)			12.4
				mean healed scar size (cm)			10.4 ± 4.6
							larvae
Marineau, 2011	Prospective	diabetic ulcer	23	mean duration of treatment (days)			11.09
	Case Series			median duration of treatment (days)			10
				number with complete debridement			17 per 23
						hydrogel	larvae
Mudge, 2014	RCT	ulcer	88	rate of complete debridement		11 per 42	31 per 46
			(49)	attrition rate, any reason		10 per 42	14 per 46
				attrition rate, infection or increased slough		9 per 42	3 per 46
				attrition rate, pain or discomfort		1 per 42	8 per 46
				attrition rate, patient request to stop treatment		0 per 42	3 per 46
				mean pain score (VAS), baseline		30.17 ± 26.44	41.54 ± 28.80
				mean pain score (VAS), final evaluation		21.80 ± 27.98	19.26 ± 21.48j
				mean number of dressing changes		5.40 ± 1.795	2.83 ± 1.102
				incidence of reappearance of slough		11 per 42	31 per 46
				number that remained debrided after complete debridement		2 per 11	9 per 31

MAGGO WOOND INEKAL							
AUTHOR, YEAR	STUDYDESIGN	WOUND TYPE	Z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES		
					CONTROL COMP	COMPARISON	TREATMENT
					conve	conventional (surgical)	bagged maggots
Opletalova, 2012	RCT	ulcer	105	mean wound surface area, baseline day one (cm²)	11.4 ± 8.1	8.1	11.5 ± 9.3
				mean percent change in wound surface, day 8*	-1.5 ± 34.3	34.3	-10.9 ± 38.1
				mean percent change in wound surface, day 15*	8.2 ± 37.9	37.9	-14.6 ± 59.6
				mean percent change in wound surface, day 30*	12.9 ± 53.0	: 53.0	-5.3 ± 104.3
				mean percent slough, baseline (day 1)	78.7 ± 23.5	23.5	79.7 ± 22.3
				mean percent slough, day 8	66.5 ± 25.2	: 25.2	54.5 ± 31.6
				mean percent slough, day 15	53.8 ± 33.6	: 33.6	55.4 ± 30.0
				mean percent slough, day 30	60.0 ± 36.4	136.4	55.4 ± 30.4
				rate of MRSA-positive, baseline day 1	7 per 50	50	9 per 49
				rate of MRSA-positive, day 15	13 per 48	r 48	6 per 48
				rate of pseudomonas-positive, baseline day 1	5 per 50	50	4 per 50
				rate of pseudomonas-positive, day 15	5 per 48	48	4 per 49
				mean pain score (VAS) overall	2.7 ± 2.6	2.6	2.3 ± 2.6
				number with crawling sensation	101 per 49	er 49	10 per 49
					stando	standard dressing (saline)	live maggots
Paul, 2009	Prospective	diabetic ulcer	54	attrition rate	1 per 30	30	4 per 29
	Case-Control			number healed	18 per 29	r 29	14 per 25
				mean length of hospital stay (days)	19.8		12.5
				number with at least one microorganism	23 per 29	r 29	18 per 25
							larvae
Pinheiro, 2015	Case Report	diabetic ulcer	П	decrease in wound area (cm²)			0.7
				duration of treatment (days)			43
					conve treatn	conventional (prior to treatment) ^p	larvae
Sherman, 1995	Self-controlled	pressure ulcer	20	number of patients observed	8 per 20	20	20 per 20
	Case-control			mean time to complete debridement (weeks)	ı		1.4
				mean change in surface area (%/week)⁴	21.8		-22

MAGGOT WOUND THERAPY	АРУ						
AUTHOR, YEAR	STUDYDESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	VTES	
					CONTROL	COMPARISON	TREATMENT
						conventional ^s	larvae ^s
Sherman, 2002	Prospective	pressure ulcer	103	number of adverse events		(not reported)	3 per 50 ^t
	Cohort		(/9)	percent of wounds completely debrided		48 (26, 70)	80 (65, 95)
				mean time to 50% debridement (weeks)		4.0 (2.6, 5.4)	1.4 (1, 1.7)
				mean time to total debridement (weeks)		17 (7, 28)	8 (6, 10)
				mean rate of change in surface area (cm2/week)		0.3 (-0.9, 1.6)	-1.6 (-2.6, -0.6)
				percent with >= 50% granulation		18 (7, 29)	51 (36, 66)
				mean time to 50% granulation (weeks)		4.7 (2.1, 7.3)	2.1 (1.7, 2.6)
				mean rate of change in granulation (%/week)		3.3 (0.9, 5.7)	13 (7, 19)
				mean total change in surface area (cm2)		6.3 (2.5, 10.1)	-7.3 (-10.4, -4.2)
				mean rate of change in surface area (cm2/week)		1.4 (0.5, 2.3)	-1.5 (-2.3, -0.7)
				mean time to complete healing (weeks)		13.4 (8. 19)	12.0 (7, 17)
					conventional only	conventional then maggot	maggot larvae
Sherman, 2003	Retrospective Cohort	diabetic ulcer	18∘	time to 50% reduction in necrotic surface area (days)	29	ſ	6
				percent necrotic tissue, two weeks	39	1	7
				percent necrotic tissue, four weeks	33 ^b	1	0
				mean debridement rate (cm2), two weeks	0	1	4.1
				percent of healthy granulation area, four weeks	15	1	56
				difference in weekly change of surface area, maggot vs conventional (cm2/week)		1.9	
				difference in percent necrotic tissue area remaining, one week	1	22	1
Sherman, 2004	Case-control	soft tissue	25 ^u	number of wounds infected		6 per 19	0 per 10
				rate of postoperative infection (%, 95% CI)		38 (13, 62)	0
				number of adverse events		(not reported)	2 per 12

THE CONTRACTOR AND ADDRESS OF THE CONTRACTOR ADDRESS OF TH	70						
AUTHOR. YEAR ST	STUDYDESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	ES	
				l	CONTROL	COMPARISON	TREATMENT
				, se	hydrogel	loose larvae	bagged larvae
Soares, 2009	RCT	ulcer	267	mean number of applications 9.2	9.2 ± 27.78	1.44 ± 1.22	1.46 ± 1.06
				mean duration of treatment (days) 43.	43.17 ± 51.76	11.95 ± 9.11	12.84 ± 11.47
				mean estimated cost per application (£)	1.50 ± 0	71.70 ± 13.40	111.90 ± 33.6
				mean estimated total cost per patient (£)¹	1596 ± 1861	1833 ± 1978	1696±1948
				mean adjusted annual costs (£)" 197	1976.4 (1521.4, 2500.2)	I	2073.1 (1724.4, 2433.4)
				mean time to healing (days)" 206	206.5 (2.02.7, 260.2)	1	204.1 (207.9, 248.3)
				mean QALYs ^m 0.5	0.540 (0.489, 0.589)	1	0.551 (0.505, 0.591)
							larvae
Turkmen, 2010	Case Series	chronic (mix)	34	number with satisfactory debridement			29 per 34
				number with granulation			29 per 34
				number healed by 10 days			27 per 34
				number of adverse events (treatment intolerance)			1 per 34
						conventional dressing	larvae
Wang, 2010	Retrospective	diabetic ulcer,	25,	mean time to granulation, diabetic ulcer (days)		6.3 ± 1.2	3.1 ± 1.2
	Cohort	pressure ulcer	8	mean time to sterilization, diabetic ulcer (days)		16.1 ± 3.8	12.0 ± 2.5
				mean time to healing, diabetic ulcer (days)		39.6 ± 13.4	26.4 ± 12.6
				mean time to granulation, pressure ulcer (days)		4.8 ± 1.0	2.5 ± 1.0
				mean time to sterilization, pressure ulcer (days)		13.1 ± 2.2	10.4 ± 1.8
				mean time to healing, pressure ulcer (days)		30.6 ± 12.2	18.7 ± 10.4
						Intrasite hydrogel	larvae
Wayman, 2000e.f	RCT	ulcer	12	mean number of nurse visits		22.17	3
				median number of nurse visits		19	3
				mean nursing time (hrs) ⁹		426.7	86.7
				median nursing time (hrs) ⁹		375	75
				mean nursing costs (£)		66.74	12.44

MAGGOT WOUND THERAPY	HERAPY						
AUTHOR, YEAR	STUDYDESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	ATES	
					CONTROL	COMPARISON	TREATMENT
				median nursing costs (£)		53.85	0.77
				mean dressing costs, dressing only (£)		106.52	11.69
				median dressing costs, dressing only (£)		89.55	9.87
				mean total costs (£)		173.26	81.98
				median total costs (£)		136.23	78.64
							larvae
Wollina, 2002n	Prospective	ulcer	30	mean wound score before treatment°			13.5 ± 1.8
	Case Series			mean wound score after treatment°			6.3 ± 2.7
				mean difference in wound score (before-after)°			7.23
				median number of treatments			1
				mean application time (days)			3.3 ± 2.2
							larvae
Wu, 2012	Case Report	burn	1	time to granulation (days)			9
0 0 0	-						

- a. 20 wounds in 18 patients.
- b. At five weeks vs 100% debrided for maggot group at four weeks.
- c. Focused on cost-benefit analysis.
- d. Larval therapy arms combined.
- e. 30-day treatment period for all; only one larval treatment was administered.
- f. One control patient switched from control to larval therapy at end of study because of persistent necrotic slough (which was then quickly healed).
 - g. Discrepancy between results text (hours) and table (min).
- h. 25 patients with diabetic foot ulcers; 18 with pressure ulcers.
- i. Started with 46 in larvae arm and 42 in hydrogel; 32 completed larvae arm; 32 completed hydrogel arm; statistics based on starting number.
- . Three patients with no data for final evaluation.
- k. Wound surface area increased for conventional arm and decreased for maggot (negative percent indicates decrease).
 - I. 77-85% of costs due to nurse consultations and hospital visits.
- m. Hydrogel compared to combined larval therapy arms.
- n. Mentions that mild pain/burning sensation was common but not in how many patients.
- o. Wound score calculated as a combined score for sloughy coverage, exudation, malodor, inflammation, granulation, each marked 0-3; maximum score 15.
- p. Conventional treatment as determined by patients' primary care providers observed in eight out of 10 patients three to four weeks prior to larvae treatment.
 - q. Positive indicates increase in wound area, negative indicates decrease.
- r. 103 patients (with 145 wounds) evaluated for adverse events; 92 wounds in 67 patients analyzed for debridement and healing.
- s. Results represented as estimate (95% confidence interval); for surface area, positive values show increase in wound area and negative show decrease.
- t. Two reported pain, one reported anxiety about treatment.
- u. 29 wounds in 25 patients.
- v. 723 wounds in 435 patients.
- w. Combined results reported on all outcome measures.
- x. Scoliosis patients with infected wounds; antibiotic treatment concurrent with maggot debridement.

POTATO PEEL							
AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	ATES	
					CONTROL	COMPARISON	TREATMENT
Manjunath, 2015	Case Report	necrotizing fasciitis	⊣	reduction in wound surface area, one week (cm2)			12
TEA TREE OIL							
AUTHOR, YEAR	STUDY DESIGN	WOUND TYPE	z	OUTCOME MEASURE (UNITS)	EFFECT ESTIMATES	ATES	
					CONTROL	COMPARISON	TREATMENT
Lee, 2014	RCT	ulcer infected	32	quantity of MRSA, baseline (CFU/ml)	-	6437±1209	7093±1356
		with MRSA		quantity of MRSA, one week (CFU/ml)		8125±1821	4531±1783
				quantity of MRSA, two weeks (CFU/ml)		8937±2174	2375±1284
				quantity of MRSA, three weeks (CFU/ml)		9875±2610	468±590
				quantity of MRSA, four weeks (CFU/ml)		10312±3054	93±201
				PUSH score, baseline		8.1	7.9
				PUSH score, one week ^a		7.6	5.5
				PUSH score, two weeks°		6.9	5.4
				PUSH score, three weeks°		5.5	1
				PUSH score, four weeks°		9.4	0
							3.3% tea tree oil
Edmondson, 2011	Case Report	MRSA	11^{b}	number reporting pain			3 per 11
				attrition rate after treatment started (adverse events)			1 per 11
				mean wound size, baseline (mm²)			2553.36
				mean wound size, last measurement (mm²)			2101.18
				mean duration of treatment, last measurement (weeks)			5.82
				median duration of treatment, last measurement (weeks)			9
				number still MRSA-positive at last measurement			12 per 12
				mortality rate			1 per 12
				mean degree of pain, baseline			4.45
				mean degree of pain, last measurement			5.09

a. Pressure Ulcer Scale for Healing (PUSH) tool 3.0 score combines scores on surface area, exudate, and wound tissue type, each on a 0-4 scale. b. 12 eligible, 11 received treatment, two completed study; 11 analyzed.

The following complementary therapies were evaluated: honey, maggot debridement, Aloe vera, Calendula officinalis, Hypericum perforatum ointment, dragon's blood, curcumin, banana leaf dressing, potato peels, and tea tree oil. Nearly all evaluated complementary therapies were found to be potentially effective, but the quality of the evidence varied widely between different treatments. The richest body of evidence was identified for honey dressing, maggot debridement, and Aloe vera.

Msiska et al. Practical Implementation of Nursing Science DOI: 10.29024/pins.31

ALOE VERA

Nine articles met the inclusion criteria (Eshqhi et al., 2010; Khorasani et al., 2009; Khorasani et al., 2011; Molazem et al., 2014; Panahi et al., 2012; Schmidt & Greenspoon, 1991; Shahzad & Ahmed, 2013; Thamlikitkul et al., 1991; Thomas et al., 1998). The studies used Aloe vera as creams or gel. Four studies compared Aloe to silver sulfadiazine dressings for treatment of burn wounds (Khorasani et al., 2009; Panahi et al., 2012; Shahzad & Ahmed, 2013; Thamlikitkul et al., 1991); three studies used standard management, simple dressings, or gauze moistened with saline as a comparison (Molazem et al., 2014; Schmidt & Greenspoon, 1991; Thomas et al., 1998); and two studies compared Aloe to a placebo (Eshghi et al., 2010; Khorasani et al., 2009). Aloe vera cream reportedly decreased pain for haemorrhoidectomy but may have increased healing time (Eshahi et al., 2010). Aloe hydrogel produced a similar outcome to moist saline gauze when treating pressure ulcers (Thomas et al., 1998). There was mixed evidence for whether Aloe improved healing time for post-operative Caesarean section wounds (Molazem et al., 2014) or increased healing time (Schmidt & Greenspoon, 1991). For burns, Aloe vera reportedly improved skin dryness, pain severity (Panahi et al., 2012) and had a high patient satisfaction rating (Thamlikitkul et al., 1991) compared to silver sulfadiazine dressings. Healing time for burn wounds for those treated with Aloe vera was similar or shorter than silver sulfadiazine dressings (Khorasani et al., 2009; Panahi et al., 2012; Shahzad & Ahmed, 2013).

Comparison of the effectiveness of nanocrystalline silver (nAg) and Aloe vera as complementary therapies

Tsang et al. (2017) conducted a randomized controlled study of nanocrystalline silver (nAg) and manuka honey (MH) compared to conventional dressing (paraffin tulle and gauze) in healing diabetic foot ulcer (DFU) in terms of ulcer healing, ulcer infection, and inflammation (listed under "Honey" in Table 2). Estimated healing potential was highest in the nAg group followed by the MH group, and both were higher than the conventional group. The ulcer size reduction rate measured by percentage of area reduction was highest in the nAg group and second highest in the MH group, both of which were at least 10 percentage points higher than the conventional group.

BANANA LEAVES

One study was included on sterilized banana leaves, which focused on direct application to surgical incision wounds (Guenova et al., 2013). Banana leaves were tested in a clinical setting in postsurgical patients in Uganda and were reported to have wound-dressing properties that equaled those of petroleum jelly gauze dressings. No additional pain during the first dressing change and no infections were reported during the two-week follow-up period.

CALENDULA OFFICINALIS

Buzzi et al. (2016) examined the effects of Calendula officinalis on patients with venous leg ulcers. The proportion of patients achieving complete epithelialization was 72% and 32% in the treatment and control groups, respectively. The average healing time was approximately 12 weeks in the treatment group and 25 weeks in control patients. Patients with ulcers treated with Calendula officinalis extract had a significant four-fold increase in percentage healing velocity per week, 7.4%, compared with 1.7% in the control group. No adverse events were observed during the Calendula officinalis extract treatment.

CURCUMIN OINTMENT (TURMERIC)

One clinical trial of high quality conducted in India was identified (Choudhary et al., 2012). Turmeric (ethanol extract of turmeric in Vaseline base after proper sterilization applied topically along with Vaseline gauze (Jelonet)) was found to be effective as an antiseptic treatment with local application for superficial burns. Patients in the test group were consistently found to have a lower rate of infection and positive swab cultures throughout the time points measured in the course of study compared to the control group (Vaseline gauze (Jalonet) alone). Also, the study found a progressive decrease in the number of positive cultures in the test group from the third day onward. No side effect was noted in either group.

DRAGON'S BLOOD TOPICAL CREAM

One clinical trial from Iran investigated whether dragon's blood was an effective and safe healing agent (Namjoyan et al., 2016). At the end of the trial, there was a significant difference in the mean duration of wound healing between the two groups, and no irritations or wound infections were reported among those in the therapy arm.

HONEY

Thirty-one studies of high to moderate quality were identified. Most were clinical trials. The efficacy of the topical use of honey was evaluated for a wide range of wound types including burns, acute, chronic, pressure, malignant, post-traumatic, and post-operative wounds.

The highest quality studies reported evidence that treating superficial and partial thickness burns with honey reduced mean time to healing in comparison with conventional non-antibacterial treatments. Additional moderate quality evidence suggested that burns treated with honey were more likely to heal over time as compared to topical antibiotics (Mashhood et al., 2006; Subrahmanyam, 1998). Some moderate quality evidence suggested that honey was more effective than antiseptics followed by gauze for post-operative infected wounds, while lower quality evidence suggested wounds treated with topical honey were less likely to get infected compared to treatments with silver-based antiseptics or topical antibiotics (Gulati et al., 2014).

Many studies including several randomized controlled trials found that the antibacterial effect of honey dressing differed depending on wound type. Studies investigating the impact of honey on diabetic and pressure foot ulcers strongly supported an antibacterial effect of honey dressing (Shukrimi et al., 2008; Dubhashi & Sindwani, 2015; Tsang et al., 2017; Kamaratos et al., 2012). Studies examining malignant wounds reached mixed conclusions; some found honey-coated and silver-coated bandages to have no effect while others showed improved outcomes (Lund-Nielsen et al., 2011). Honey dressing reportedly performed comparably to phenytoin cream and even superior to silver sulfadiazine (Mashhood et al., 2006; Subrahmanyam, 1998). Studies also referenced numerous other benefits associated with the use of honey dressing, including increase of patient comfort, better pain management, faster and more efficient removal of malodor, decrease in wound size, and fast disinfection (Dorai, 2012; Dubhashi & Sindwani, 2015; Gulati et al., 2014; Kamaratos et al., 2012). Several trials highlighted an improved aesthetic outcome of the wound by using honey dressing (Dorai, 2012).

HYPERICUM PERFORATUM

Only one study on Hypericum perforatum was included (Samadi et al., 2010). Hypericum perforatum ointment was compared to placebo as a treatment for Caesarean section wounds. There were significant differences in wound healing on the 10th day and scar formation on the 40th day postpartum between the treatment group and the placebo and control groups. The placebo group had no differences in wound healing and scar formation from the control group. In addition, significantly lower pain and pruritus were reported by the treatment group compared with the placebo and control groups on the 40th day postpartum.

MAGGOT DEBRIDEMENT

Nineteen studies varying in quality were identified, with high prevalence of meta-analyses, systematic reviews, and case reports. The majority of available evidence investigated patients with different types of ulcers and other chronic wounds.

Maggot therapy was found to influence three processes: tissue granulation, debridement, and infection. An increase in wound granulation tissue and quicker debridement (average within one week) were shown in numerous studies (Wayman et al., 2000; Wollina et al., 2002; (Marineau et al., 2011; Turkmen et al., 2010). Studies reached mixed conclusions regarding disinfection; some seem to confirm the disinfecting properties of this therapy (Sherman et al., 1995; Sherman & Shimoda, 2004), while the others found no difference in infection rates between larval and conventional therapies (Opletalová et al., 2012). Bio-surgical properties of maggot therapy such as healing time, complete healing rate, and amputation rate were evaluated. Their translation into clinical outcomes varied. The evidence showed a consistent significant decrease in amputation rate only regarding time to heal; most of the studies found larval therapy groups with significantly shorter healing time (Sherman, 2003; Azad et al., 2016; Wu et al., 2012), but other studies showed no difference (Paul et al., 2009; Dumville et al., 2009; Soares et al., 2009). While some studies showed improvement in full healing rate after implementation of larval therapy, numerous other reviews and meta-analyses failed to show any significant improvement in complete healing rate following maggot debridement therapy.

Studies performing cost-effectiveness analyses also reached mixed conclusions. Most of them found larval therapy to be more cost-effective than conventional therapies due to shortening the length of hospital stay and reducing the need for amputation. Increase in wound granulation tissue and quick debridement (average within one week) were shown in numerous studies. A few studies (Soares et al., 2009) suggested the costs of larval therapy may be similar to those of hydrogel-based therapies.

POTATO PEELS

Only two studies focused on potato peels as a potential wound treatment. One study included 100 patients with burn injuries and compared treatment with potato peels to honey (Subrahmanyam, 1996a, listed under "Honey" in Table 2), and the other was a case study (Manjunath et al., 2015). In the patients treated with honey, 90% of wounds were rendered sterile within seven days, but infections persisted in patients treated with potato peels in the same period. Potato peels were also not found to improve total healing time compared to treatment with honey; 100% of patients with burn wounds treated with honey healed within 15 days versus only 50% with wounds treated with boiled potato peel dressings. Potentially positive results of potato peels that were reported included a fast rate of formation of healthy granulation tissue and good marginal healing.

TEA TREE OIL

There were only two studies on tea tree oil as a wound treatment for patients with stage II or higher MRSA-colonized wounds. In the tea tree oil group, all chronic wounds that had previously been delayed in healing were healed within the study period without adverse reaction. In the study by Lee et al. (2014), MRSA was also completely eradicated in 87% of wounds in the group receiving the 10% topical tea tree oil preparation by the end of the study period. Sixteen MRSA colonized wounds in the tea tree oil group were closed skin by 28 days. After treatment, eight of the 11 treated wounds had begun to heal and reduced in size. In another study, no participants were MRSA negative after treatment (Edmondson et al., 2011), but this study had a smaller sample size, used a lower dose of tea-tree oil, and a "rinse-off" treatment, rather than "leave-on" treatment.

DISCUSSION

ALOE VERA

The results suggest that Aloe vera improved pain, was well tolerated, and had similar or better wound healing rates compared to silver sulfadiazine dressings in treating burn wounds. Aloe vera also improved healing time after haemorrhoidectomy and skin graft. On the other hand, in chronic wounds such as pressure ulcers, there was no statistical difference in the healing process, and in post-Caesarean wounds, adding Aloe to standard treatment sometimes extended healing time. The results suggest that there is need for more studies to understand for which types of wounds Aloe vera can improve healing and for which it either makes no difference or slows healing.

BANANA LEAVES

The study on sterilized banana leaves used as wound dressings could serve as a proof of concept. Though there was limited evidence to support the hypothesis that a special chemical found in the leaves could proactively promote healing and reduce infectious bacteria, in application, the rate of discomfort and complications for banana leaf dressings were found to be comparable to conventional dressings, suggesting they could be used as a lower cost alternative.

CALENDULA OFFICINALIS

Calendula oil (or Calendula officinalis extract) may aid in wound healing by promoting epithelial growth and by enhancing immune responses. While the studies suggest efficacy for venous and diabetic leg ulcers and post-cesarean section wounds, further research is needed to validate this result.

CURCUMIN OINTMENT (TURMERIC)

The study on turmeric cream reported this to be a painless treatment, even suggesting that turmeric was soothing on local application for superficial burn would patients. Although the one randomized controlled trial identified suggested that it could be a safe and effective treatment for wound healing, further studies are needed to support this statement.

DRAGON'S BLOOD TOPICAL CREAM

While the results for the use of dragon's blood were promising, these were from only one clinical trial. Also, there is no clear understanding of the role of pathogenesis of wound healing. As such, there is need to conduct more studies to test its effectiveness on stimulation or hindering of mediators in wound healing. Additionally, there are a number of studies published in Chinese that were not evaluated in this systematic review.

HONEY

Honey had the largest body of literature studying its effectiveness for wound therapy. Most studies found that it was effective for burn wounds and diabetic ulcers; this may be especially important in resource-limited settings. Notably, nine studies on honey therapy were conducted by one researcher (Subrahmanyam).

HYPERICUM PERFORATUM

Evidence on the effectiveness of Hypericum perforatum in wound healing was scant. The primary benefit found in one study was that Hypericum perforatum may increase patient comfort. More research would help determine the usefulness of Hypericum perforatum in wound healing.

MAGGOT DEBRIDEMENT

There was a large body of literature evaluating the efficacy of maggot debridement therapy, and most studies showed it was effective particularly in treating chronic ulcers and preventing

amputations. Also, many studies concluded that larval therapy was more cost-effective than conventional treatments.

Msiska et al.
Practical Implementation
of Nursing Science
DOI: 10.29024/pins.31

POTATO PEELS

The limited evidence on potato peels suggests they are not an efficacious wound treatment. In a direct comparison, honey, which also had a larger evidence base, was shown to be more effective.

TEA TREE OIL

There was some evidence showing that tea tree oil could be helpful in treating MRSA colonized wounds; however, neither complete healing nor eradication of MRSA was achieved. Further research is need to support the use of tea tree oil for a treatment for MRSA colonized wounds, though it may have utility when conventional treatments are unavailable.

CONCLUSION

This review evaluated the available published evidence on the clinical effectiveness of complementary therapies in wound treatment and identified several that may be therapeutically effective and more cost-effective than conventional treatments. All complementary therapies reviewed except for potato peels had at least one study that found them to be potentially effective, though the quality of the evidence varied. Out of the studies identified, few contained high quality evidence, and some articles were case studies. The richest bodies of evidence were identified for honey dressing, maggot debridement, and Aloe vera, which all demonstrated effectiveness in the treatment of chronic wounds. While additional high-quality studies are needed across settings to understand effectiveness, best practices, and indications, the results of this systematic review can assist in guiding practitioners to identify options for lower-cost, potentially efficacious wound treatments.

ACKNOWLEDGEMENTS

We gratefully acknowledge the support of Ediom's EvidenceEngine, Ray Liu, and Sally Yin for their support of our project. We also thank Columbia University School of Nursing's Global Innovation Fund for the Writing to Improve Nursing Science in Malawi grant that supported this work, as well as the partnership and contribution from University of Malawi Kamuzu University of Health Sciences, formerly Kamuzu College of Nursing. We are grateful for all the staff and faculty that supported this project from University of Malawi Kamuzu College of Nursing. Finally, we thank Yu-Hui Ferng for arranging and supporting our in-person writing workshop, Drs. Ana Kelly and Maureen George for serving as co-investigators on the Writing to Improve Nursing Science in Malawi grant, and Dr. Tonda Hughes and Dr. Jennifer Dohrn for their insight and support for the project.

FUNDING INFORMATION

This study was funded by the Columbia University School of Nursing's Global Innovation Fund.

COMPETING INTERESTS

The authors have no competing interests to declare.

AUTHOR AFFILIATIONS

Gladys Msiska orcid.org/0000-0001-5606-639X Kamuzu University of Health Sciences, MW Caroline Fu orcid.org/0000-0003-3905-8085 NYC Administration for Children's Services, US **Kondwani Wella** orcid.org/0000-0001-7506-7777

Kamuzu University of Health Sciences, MW

Annie Msosa orcid.org/0009-0003-6024-8008

Kamuzu University of Health Sciences, MW

Noel Mbirimtengerenji

Kamuzu University of Health Sciences, MW

Gibson Masache orcid.org/0000-0002-8752-6181

Kamuzu University of Health Sciences, MW

Miriam Simbota

Kamuzu University of Health Sciences, MW

Mara Chris Banez orcid.org/0000-0002-9868-3174

NewYork-Presbyterian Weill Cornell, US

Genesis Chorwe-Sungani orcid.org/0000-0002-4296-6394

Kamuzu University of Health Sciences, MW

Carolyn Sun, PhD, ANP-BC, RN D orcid.org/0000-0001-9628-6901

Hunter College, US

REFERENCES

Azad, A., Sulaiman, W., Adham, S., & **Yee, B.** (2016). Maggot debridement therapy for diabetic foot ulcer: Experience from Maggot treatment Centers. *Asian Journal of Pharmacy and Pharmacology*, 2(1), 23–25.

Baghel, P. S., Shukla, S., Mathur, R. K., & Randa, R. (2009). A comparative study to evaluate the effect of honey dressing and silver sulfadiazene dressing on wound healing in burn patients. *Indian Journal of Plastic Surgery*, 42(2), 176–181. DOI: https://doi.org/10.4103/0970-0358.59276

Bangroo, A., Khatri, R., & **Chauhan, S.** (2005). Honey dressing in pediatric burns. *Journal of Indian Association of Pediatric Surgeons*, 10(3), 172–175. DOI: https://doi.org/10.4103/0971-9261.16970

Benskin, L. L. (2013). A review of the literature informing affordable, available wound management choices for rural areas of tropical developing countries. *Ostomy Wound Management*, 59(10), 20–41. DOI: https://doi.org/10.25270/owm.2013.10.2041

Biglari, B., Vd Linden, P., Simon, A., Aytac, S., Gerner, H., & **Moghaddam, A. J.** (2012). Use of Medihoney as a non-surgical therapy for chronic pressure ulcers in patients with spinal cord injury. *Spinal Cord*, 50(2), 165. DOI: https://doi.org/10.1038/sc.2011.87

Buzzi, M., de Freitas, F., & **de Barros Winter, M.** (2016). Therapeutic effectiveness of a Calendula officinalis extract in venous leg ulcer healing. *Journal of Wound Care*, 25(12), 732–739. DOI: https://doi.org/10.12968/jowc.2016.25.12.732

Chokotho, L., Mulwafu, W., Jacobsen, K. H., Pandit, H., & Lavy, C. (2014). The burden of trauma in four rural district hospitals in Malawi: A retrospective review of medical records. *Injury*, 45(12), 2065–2070. DOI: https://doi.org/10.1016/j.injury.2014.10.001

Choudhary, S.K., Sharma, R., & **Chourishi, A.** (2012). Antiseptic and healing effects of turmeric ointment on local application in superficial burn. *International Journal of Bioassays*, *01*(11), 138–140.

D'Agostino, G., Ollik, M., Liu, R., & **Ferguson, Z.** (2018). 29 Manual versus machine-assisted: a case study comparing a manual systematic literature review to a computer-assisted evidence search and synthesis approach (evidenceenginetm). *BMJ Evidence-Based Medicine*, 23(Suppl 1), A15. DOI: https://doi.org/10.1177/0268355514555386

Dorai, A. (2012). Wound care with traditional, complementary and alternative medicine. *Indian Journal of Plastic Surgery*, 45(2), 418. DOI: https://doi.org/10.4103/0970-0358.101331

Dryden, M., Tawse, C., Adams, J., Howard, A., Saeed, K., & **Cooke, J.** (2014). The use of Surgihoney to prevent or eradicate bacterial colonisation in dressing oncology long vascular lines. *Journal of Wound Care*, 23(6), 338–341. DOI: https://doi.org/10.12968/jowc.2014.23.6.338

Dubhashi, S. P., & **Sindwani, R. D.** (2015). A comparative study of honey and phenytoin dressings for chronic wounds. *Indian Journal of Surgery*, 77(3), 1209–1213. DOI: https://doi.org/10.1007/s12262-015-1251-6

Dumville, J. C., Worthy, G., Bland, J. M., et al. (2009). Larval therapy for leg ulcers (VenUS II): Randomised controlled trial. *British Medical Journal*, 338, b773. DOI: https://doi.org/10.1136/bmj.b773

Edmondson, M., Newall, N., Carville, K., Smith, J., Riley, T., & Carson, C. (2011). Uncontrolled, open-label, pilot study of tea tree (Melaleuca alternifolia) oil solution in the decolonisation of methicillin-resistant Staphylococcus aureus positive wounds and its influence on wound healing. *International Wound Journal*, 8(4), 375–384. DOI: https://doi.org/10.1111/j.1742-481X.2011.00801.x

- **Erwin-Toth, P.** (2014). The Use of Alternative and Complementary Therapy in Wound Care. https://www.woundsource.com/blog/use-alternative-and-complementary-therapy-wound-care
- Eshghi, F., Hosseinimehr, S. J., Rahmani, N., Khademloo, M., Norozi, M. S., & Hojati, O. (2010). Effects of Aloe vera cream on posthemorrhoidectomy pain and wound healing: Results of a randomized, blind, placebo-control study. *Journal of Alternative Complementary Medicine*, 16(6), 647–650. DOI: https://doi.org/10.1089/acm.2009.0428
- **Gilead, L., Mumcuoglu, K., & Ingber, A.** (2012). The use of maggot debridement therapy in the treatment of chronic wounds in hospitalised and ambulatory patients. *Journal of Wound Care*, 21(2), 78–85. DOI: https://doi.org/10.12968/jowc.2012.21.2.78
- **Guenova, E., Hoetzenecker, W., Kisuze, G.,** et al. (2013). Banana leaves as an alternative wound dressing. *Dermatologic Surgery*, 39(2), 290–297. DOI: https://doi.org/10.1111/dsu.12067
- **Gulati, S., Qureshi, A., Srivastava, A., Kataria, K., Kumar, P.,** & **Ji, A. B.** (2014). A prospective randomized study to compare the effectiveness of honey dressing vs. povidone iodine dressing in chronic wound healing. *Indian Journal of Surgery*, 76(3), 193–198. DOI: https://doi.org/10.1007/s12262-012-0682-6
- **Gupta, S. S., Singh, O., Bhagel, P. S.,** et al. (2011). Honey dressing versus silver sulfadiazene dressing for wound healing in burn patients: A retrospective study. *Journal of Cutaneous and Aesthetic Surgery*, 4(3), 183. DOI: https://doi.org/10.4103/0974-2077.91249
- **Haagsma, J. A., Graetz, N., Bolliger, I.,** et al. (2016). The global burden of injury: Incidence, mortality, disability-adjusted life years and time trends from the Global Burden of Disease study 2013. *Injury Prevention*, 22(1), 3–18. DOI: https://doi.org/10.1136/injuryprev-2015-041616
- **Hwang, J., Modi, H., Suh, S., Hong, J., Yang, J.,** & **Park, J.** (2011). Maggot debridement therapy for postsurgical wound infection in scoliosis: A case series in five patients. *Spine*, *36*(4), 313–319. DOI: https://doi.org/10.1097/BRS.0b013e3181cd3076
- **Ingle, R., Levin, J.,** & **Polinder, K. J.** (2006). Wound healing with honey: A randomised controlled trial. *South African Medical Journal*, 96(9), 831–835.
- Joanna Briggs Institute. (2014). Joanna Briggs Institute Reviewers' Manual: 2014.
- **Jull, A., Walker, N., Parag, V., Molan, P.,** & **Rodgers, A.** (2008). Randomized clinical trial of honey-impregnated dressings for venous leg ulcers. *British Journal of Surgery*, 95(2), 175–182. DOI: https://doi.org/10.1002/bjs.6059
- Kamaratos, A. V., Tzirogiannis, K. N., Iraklianou, S. A., Panoutsopoulos, G. I., I. E. K., & Melidonis, A. I. (2012). Manuka honey-impregnated dressings in the treatment of neuropathic diabetic foot ulcers. International Wound Journal, 11(3), 259–63. DOI: https://doi.org/10.1111/j.1742-481X.2012.01082.x
- Khorasani, G., Hosseinimehr, S.J., Azadbakht, M., Zamani, A., & Mahdavi, M. R. (2009). Aloe versus silver sulfadiazine creams for second-degree burns: A randomized controlled study. Surgery Today, 39(7), 587–591. DOI: https://doi.org/10.1007/s00595-008-3944-y
- Khorasani, G., Ahmadi, A., Jalal Hosseinimehr, S., Ahmadi, A., Taheri, A., & Fathi, H. (2011). The effects of Aloe vera cream on split-thickness skin graft donor site management: a randomized, blinded, placebocontrolled study. *Wounds*, 23(2), 44.
- **Lee, R., Leung, P., & Wong, T.** (2014). A randomized controlled trial of topical tea tree preparation for MRSA colonized wounds. *International Journal of Nursing Sciences*, 1(1), 7–14. DOI: https://doi.org/10.1016/j.ijnss.2014.01.001
- **Lund-Nielsen, B., Adamsen, L., Kolmos, H.J.,** et al. (2011). The effect of honey-coated bandages compared with silver-coated bandages on treatment of malignant wounds: A randomized study. *Wound Repair and Regeneration*, 19(6), 664-670. DOI: https://doi.org/10.1111/j.1524-475X.2011.00735.x
- Maghsoudi, H., Salehi, F., Khosrowshahi, M. K., Baghaei, M., Nasirzadeh, M., & Shams, R. (2011).

 Comparison between topical honey and mafenide acetate in treatment of burn wounds. *Annals of Burns and Fire Disasters*, 24(3), 132–137.
- Malik, K. I., Malik, M. N., & Aslam, A. (2010). Honey compared with silver sulphadiazine in the treatment of superficial partial-thickness burns. *International Wound Journal*, 7(5), 413–417. DOI: https://doi.org/10.1111/j.1742-481X.2010.00717.x
- Manjunath, K., Bhandage, S., & Kamat, S. (2015). 'Potato Peel Dressing': A Novel Adjunctive in the Management of Necrotizing Fasciitis. *Journal of Oral and Maxillofacial Surgery*, 14(Suppl 1), 352–354. DOI: https://doi.org/10.1007/s12663-013-0590-8
- **Marineau, M., Herrington, M., Swenor, K.,** & **Eron, L.** (2011). Maggot debridement therapy in the treatment of complex diabetic wounds. *Hawaii Medical Journal*, 70(6), 121.
- Marshall, C., Queen, J., & Manjooran, J. J. (2005). Honey vs povidone iodine following toenail surgery. Wounds UK, 1(1), 10.

- **Mashhood, A. A, Khan, T. A.,** & **Sami, A. N.** (2006). Honey compared with 1% silver sulfadiazine cream in the treatment of superficial and partial thickness burns. *Journal of Pakistan Association of Dermatologists*, 16(1), 14–19.
- **McIntosh, C.,** & **Thomson, C.** (2006). Honey Dressings versus Paraffin Tulle Gras following Toenail Surgery. *Journal of Wound Care*, 15, 133–136. DOI: https://doi.org/10.12968/jowc.2006.15.3.26877
- Memon, A. R., Tahir, S., Khushk, I. A., & Memon, G. A. (2005). Therapeutic effects of honey versus silver sulfadiazine in the management of burn injuries. *Journal of Liaquat University Medicine and Health Sciences*, 100–104. DOI: https://doi.org/10.22442/jlumhs.05430069
- Moher, D., Liberati, A., Tetzlaff, J., & Altman, D. G. (2009). Reprint—Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Physical Therapy*, 89(9), 873–880. DOI: https://doi.org/10.1093/ptj/89.9.873
- Molazem, Z., Mohseni, F., Younesi, M., & Keshavarzi, S. (2014). Aloe vera gel and cesarean wound healing; A randomized controlled clinical trial. *Global Journal of Health Science*, 7(1), 203–209. DOI: https://doi.org/10.5539/gjhs.v7n1p203
- Mudge, E., Price, P., Walkley, N., & Harding, K. G. (2014). A randomized controlled trial of larval therapy for the debridement of leg ulcers: results of a multicenter, randomized, controlled, open, observer blind, parallel group study. Wound Repair and Regeneration, 22(1), 43–51. DOI: https://doi.org/10.1111/wrr.12127
- Namjoyan, F., Kiashi, F., Moosavi, Z. B., Saffari, F., & Makhmalzadeh, B. S. (2016). Efficacy of Dragon's blood cream on wound healing: A randomized, double-blind, placebo-controlled clinical trial. *Journal of Traditional Complementary Medicine*, 6(1), 37–40. DOI: https://doi.org/10.1016/j.jtcme.2014.11.029
- National Statistical Office. (2017). Malawi Demographic and Health Survey 2015-16.

39-46. DOI: https://doi.org/10.1111/j.1742-481X.2008.00564.x

- Nilforoushzadeh, M. A., Jaffary, F., Moradi, S., Derakhshan, R., & Haftbaradaran, E. (2007). Effect of topical honey application along with intralesional injection of glucantime in the treatment of cutaneous leishmaniasis. *BMC Complementary Medicine and Therapies*, 7(1), 13. DOI: https://doi.org/10.1186/1472-6882-7-13
- **Opletalová, K., Blaizot, X., & Mourgeon, B.,** et al. (2012). Maggot Therapy for Wound Debridement: A Randomized Multicenter Trial. *Archives of Dermatology*, 148(4), 432–438. DOI: https://doi.org/10.1001/archdermatol.2011.1895
- **Panahi, Y., Davoudi, S. M., Sahebkar, A.,** et al. (2012). Efficacy of Aloe vera/olive oil cream versus betamethasone cream for chronic skin lesions following sulfur mustard exposure: A randomized double-blind clinical trial. *Cutaneous and Ocular Toxicology*, 31(2), 95–103. DOI: https://doi.org/10.3109/155695 27.2011.614669
- Posnett, J., & Franks, P.J. (2008). The burden of chronic wounds in the UK. Nursing Times, 104(3), 44–45.
 Paul, A. G., Ahmad, N. W., Lee, H. L., et al. (2009). Maggot debridement therapy with Lucilia cuprina: A comparison with conventional debridement in diabetic foot ulcers. International Wound Journal, 6(1),
- **Pinheiro, M., Ferraz, J., Junior, M.,** et al. (2015). Use of maggot therapy for treating a diabetic foot ulcer colonized by multidrug resistant bacteria in Brazil. *Indian Journal of Medical Research*, 141(3), 340. DOI: https://doi.org/10.4103/0971-5916.156628
- **Queen, D.,** & **Harding, K.** (2012). National approaches to wound treatment and prevention. *International Wound Journal*, 9(4), 349. DOI: https://doi.org/10.1111/j.1742-481X.2012.01053.x
- Robson, V., Dodd, S., & Thomas, S. (2009). Standardized antibacterial honey (Medihoney™) with standard therapy in wound care: Randomized clinical trial. *Journal of Advanced Nursing*, 65(3), 565–575. DOI: https://doi.org/10.1111/j.1365-2648.2008.04923.x
- **Rutkowski, M., Jasonek, D., Kalinowska, A.,** et al. (2018). 71 Do robotic-supported prostatectomies provide superior clinical outcomes over traditional techniques? Application of a novel, quantitative approach for evaluating clinical evidence. *BMJ Evidence-Based Medicine*, 23(Suppl 1), A35–36. DOI: https://doi.org/10.1136/bmjebm-2018-111024.71
- **Samadi, S., Khadivzadeh, T., Emami, A.,** et al. (2010). The effect of Hypericum perforatum on the wound healing and scar of cesarean. *Journal of Alternataive Complementary Medicine*, 16(1), 113–117. DOI: https://doi.org/10.1089/acm.2009.0317
- **Schmidt, J. M.,** & **Greenspoon, J. S.** (1991). Aloe vera dermal wound gel is associated with a delay in wound healing. *Obstetrics & Gynecology*, 78(1), 115–117.
- **Sen, C. K.** (2019). Human Wounds and Its Burden: An Updated Compendium of Estimates. *Advances in Wound Care*, 8(2), 39–48. Epub 2019 Feb 13. PMID: 30809421; PMCID: PMC6389759. DOI: https://doi.org/10.1089/wound.2019.0946

- **Shahzad, M. N.,** & **Ahmed, N.** (2013). Effectiveness of Aloe vera gel compared with 1% silver sulphadiazine cream as burn wound dressing in second degree burns. *Journal of Pakistan Medical Association*, 63(2), 225–230.
- **Sherman, R.** (2002). Maggot Therapy for Foot and Leg Wounds. *International Journal of Lower Extremity Wounds*, 1(2), 135–142. DOI: https://doi.org/10.1177/1534734602001002009
- **Sherman, R.** (2003). Maggot Therapy for Treating Diabetic Foot Ulcers Unresponsive to Conventional Therapy. *Diabetes Care*, 26(2), 446–451. DOI: https://doi.org/10.2337/diacare.26.2.446
- **Sherman, R.,** & **Shimoda, K.** (2004). Presurgical Maggot Debridement of Soft Tissue Wounds Is Associated with Decreased Rates of Postoperative Infection. *Clinical Infectious Diseases*, 39(7), 1067–1070. DOI: https://doi.org/10.1086/423806
- **Sherman, R., Wyle, F.,** & **Vulpe, M.** (1995). Maggot therapy for pressure sores in spinal cord injury patients. *Journal of Spinal Cord Medicine*, 18, 71–74. DOI: https://doi.org/10.1080/10790268.1995.11719382
- **Shukrimi, A., Sulaiman, A.R., Halim, A.Y.,** & **Azril, A.** (2008). A comparative study between honey and povidone iodine as dressing solution for Wagner type II diabetic foot ulcers. *Medical Journal of Malaysia*, 63(1), 44–46.
- Sibbald, R. G., Ayello, E. A., Smart, H., Goodman, L., & Ostrow, B. (2012). A global perspective of Wound Care(c). Advances in Skin & Wound Care, 25(2), 77–86. DOI: https://doi.org/10.1097/01. ASW.0000411408.97930.af
- Soares, M. O., Iglesias, C. P., Bland, J. M., et al. (2009). Cost effectiveness analysis of larval therapy for leg ulcers. *British Medical Journal*, 338, b825–b825. DOI: https://doi.org/10.1136/bmj.b825
- **Subrahmanyam, M.** (1991). Topical application of honey in treatment of burns. *British Journal of Surgery*, 78(4), 497–498. DOI: https://doi.org/10.1002/bjs.1800780435
- **Subrahmanyam, M.** (1993a). Honey impregnated gauze versus polyurethane film (OpSiteR) in the treatment of burns: A prospective randomised study. *British Journal of Plastic Surgery*, 46(4), 322–323. DOI: https://doi.org/10.1016/0007-1226(93)90012-Z
- **Subrahmanyam, M.** (1994). Honey-impregnated gauze versus amniotic membrane in the treatment of burns. *Burns*, 20(4), 331–333. DOI: https://doi.org/10.1016/0305-4179(94)90061-2
- **Subrahmanyam, M.** (1996a). Honey dressing versus boiled potato peel in the treatment of burns: A prospective randomized study. *Burns*, 22(6), 491–493. DOI: https://doi.org/10.1016/0305-4179(96)00007-1
- **Subrahmanyam, N.** (1996b). Addition of antioxidants and polyethylene glycol 4000 enhances the healing property of honey in burns. *Annals of Burns and Fire Disasters*, 9(2).
- **Subrahmanyam, M.** (1998). A prospective randomised clinical and histological study of superficial burn wound healing with honey and silver sulfadiazine. *Burns*, 24(2), 157–161. DOI: https://doi.org/10.1016/S0305-4179(97)00113-7
- **Subrahmanyam, M.** (1999). Early tangential excision and skin grafting of moderate burns is superior to honey dressing: A prospective randomised trial. *Burns*, 25(8), 729–731.
- **Subrahmanyam, M.,** & **Ugane, S.** (2004). Honey dressing beneficial in treatment of Fournier's gangrene. *Indian Journal of Surgery*, 66(2).
- **Subrahmanyam M.** (2015). Honey Dressing Accelerates Split-Thickness Skin Graft Donor Site Healing. *The Indian Journal of Surgery*, 77(Suppl 2), 261–263. DOI: https://doi.org/10.1007/s12262-012-0789-9
- **Thamlikitkul, V., Bunyapraphatsara, N.,** & **Riewpaiboon, W.,** et al. (1991). Controlled Trial of Aloe vera Linn. for Treatment of Minor Burns. *Siriraj Hospital Gazette*, 43(5), 313–316.
- **Thomas, D. R., Goode, P. S., LaMaster, K.,** & **Tennyson, T.** (1998). Acemannan Hydrogel Dressing versus Saline Dressing for Pressure Ulcers: A Randomized, Controlled Trial. *Advances in Skin & Wound Care*, 11(6), 273–276.
- **Thomas, M., Hamdan, M., Hailes, S.,** & **Walker, M.** (2011). Manuka honey as an effective treatment for chronic pilonidal sinus wounds. *Journal of Wound Care*, 20(11), 528, 530–523. DOI: https://doi.org/10.12968/jowc.2011.20.11.528
- **Tsang, K., Kwong, E., To, T., Chung, J., & Wong, T.** (2017). A pilot randomized, controlled study of nanocrystalline silver, manuka honey, and conventional dressing in healing diabetic foot ulcer. *Evidence-Based Complementary and Alternative Medicine*. DOI: https://doi.org/10.1155/2017/5294890
- **Turkmen, A., Graham, K.,** & **McGrouther, D.** (2010). Therapeutic applications of the larvae for wound debridement. *Journal of Plastic, Reconstructive & Aesthetic Surgery*, 63(1), 184–188. DOI: https://doi.org/10.1016/j.bjps.2008.08.070
- Wang, S., Wang, J., Lv, D., Diao, Y., & Zhang, Z. (2010). Clinical research on the bio-debridement effect of maggot therapy for treatment of chronically infected lesions. *Orthopaedic Surgery*, 2(3), 201–206. DOI: https://doi.org/10.1111/j.1757-7861.2010.00087.x

Wayman, J., Nirojogi, V., Walker, A., Sowinski, A., & Walker, M.A. (2000). The cost effectiveness of larval therapy in venous ulcers. *Journal of Tissue Viability*, 10(3), 91–94. DOI: https://doi.org/10.1016/S0965-206X(00)80036-4

Wollina, U., Liebold, K., Schmidt, W., Hartmann, M., & Fassler, D. (2002). Biosurgery supports granulation and debridement in chronic wounds: Clinical data and remittance spectroscopy measurement.

International Journal of Dermatology, 41(10), 635–639. DOI: https://doi.org/10.1046/j.1365-4362.2002.01354.x

World Health Organization. (2009). Global health risks: Mortality and burden of disease attributable to selected major risks. Geneva.

World Health Organization. (2019). *Road traffic injuries.* https://www.who.int/news-room/fact-sheets/detail/road-traffic-injuries

World Health Organization. (2015). Global status report on road safety: Time for action.

Wu, J., Lu, R., Huo, R., & **Fu, H.** (2012). Maggot therapy for repairing serious infective wound in a severely burned patient. *Chinese Journal of Traumatology*, 15(2), 124–125.

Msiska et al.
Practical Implementation
of Nursing Science
DOI: 10.29024/pins.31

TO CITE THIS ARTICLE:

Msiska, G., Fu, C., Wella, K., Msosa, A., Mbirimtengerenji, N., Masache, G., Simbota, M., Banez, M. C., Chorwe-Sungani, G., & Sun, C. (2023). Effectiveness of Complementary Therapies in the Management of Wounds Among Adult Patients. *Practical Implementation of Nursing Science*, 2(1), pp. 22–53. DOI: https://doi.org/10.29024/pins.31

Submitted: 19 April 2022 Accepted: 23 May 2023 Published: 08 June 2023

COPYRIGHT:

© 2023 The Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC-BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. See http://creativecommons.org/licenses/by/4.0/.

Practical Implementation of Nursing Science is a peerreviewed open access journal published by Levy Library Press.



